Researchers at St. Jude developed an anti-CD7 chimeric antigen receptor (CD7 CAR) to use for treating hematologic cancers expressing the CD7 gene, which include lymphoblastic T-cell leukemia and lymphomas. The majority of T-cells, approximately 90%, express CD7 and are removed before transduction. The CD7 CAR is introduced into the remaining subset of T cells that do not naturally express CD7.
chimeric antigen receptor, gene therapy vector, anti-CD7-CAR, T-cell malignancies
Granted Patents or Published Applications
International application published as WO 2017 213979 A1, US Pending
Related Scientific References
Please contact us if you are interested in licensing this technology. Contact: email@example.com.
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.